Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Pareto Securities AB and Swedbank AB (publ) in connection with a bond issue with a framework amount of up to MSEK 700
Mandate

Vinge has advised Pareto Securities AB and Swedbank AB (publ) in connection with a bond issue with a framework amount of up to MSEK 700

December 18, 2017 Banking and Finance

Vinge has advised Pareto Securities AB and Swedbank AB (publ) in connection with a bond issue with a framework amount of up to MSEK 700 senior unsecured floating rate bonds, issued by Offentliga Hus i Norden AB (publ) (”Offentliga Hus”) on 15 December 2017.

Pareto Securities AB and Swedbank AB (publ) have acted as arrangers and Swedbank AB (publ) also acted as issuing agent. The bonds have a tenor of three and a half years and a floating interest rate of three-months STIBOR plus a margin of 7.00 per cent.
 
The proceeds from the bond issue will be applied towards financing property acquisitions and other general corporate purposes. Offentliga Hus intends to apply for the bonds to be listed on Nasdaq Stockholm.
 
Vinges team consisted inter alia of Louise Brorsson Salomon, Lionardo Ojeda and Sara Osman.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

 Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025